Company: CRL
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001100682-25-000034
Chunk: 38

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 2
Chunk 38
---
 current business plan, we believe that our existing funds, when combined with cash generated from operations and our access to financing resources, are sufficient to fund our operations for the foreseeable future.

The following table presents our cash, cash equivalents and short-term investments: 

June 28, 2025December 28, 2024(in thousands)Cash and cash equivalents:Held in U.S. entities$2,072 $4,219 Held in non-U.S. entities180,752 190,387 Total cash and cash equivalents182,824 194,606 Short-term investments:Held in non-U.S. entities65 62 Total cash, cash equivalents and short-term investments$182,889 $194,668 

34 

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

The following table presents our net cash provided by operating activities:

Six Months EndedJune 28, 2025June 29, 2024(in thousands)Net income$78,571 $168,743 Adjustments to reconcile net income to net cash provided by operating activities285,275 214,104 Changes in assets and liabilities12,454 (59,424)Net cash provided by operating activities$376,300 $323,423 

Net cash provided by cash flows from operating activities represents the cash receipts and disbursements related to all of our activities other than investing and financing activities. Operating cash flow is derived by adjusting our net income for (1) non-cash operating items such as depreciation and amortization, stock-based compensation, goodwill impairment, debt financing costs, deferred income taxes, write downs of inventories, provisions of credit losses, long-lived asset impairment changes, gains and/or losses on venture capital and strategic equity investments, gains and/or losses on divestitures, changes in fair value of contingent consideration, as well as (2) changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our results of operations. 

During the six months ended June 28, 2025, our cash flows from operations were $376.3 million compared with $323.4 million for the same period in 2024. The increase was primarily driven by lower payments of variable compensation and favorable timing of payments to our suppliers and vendors, partially offset by higher purchases of inventory to support our DSA reportable segment.

The following table presents our net cash used in investing activities:

Six Months